[Stereotactic body radiotherapy of oligometastases: Main pending trials and to come in France].

[Stereotactic body radiotherapy of oligometastases: Main pending trials and to come in France]. Cancer Radiother. 2019 Aug 27;: Authors: Giraud P, Tournat H, Kreps S, Bibault JE, Dautruche A, Fabiano E, Feutren T, Durdux C Abstract Stereotactic radiotherapy of oligometastases, mono- or hypofractionated, represents a fundamental change in the practice of the specialty as it was developed for a century. Despite the great heterogeneity of sites, techniques, and doses, most studies found a high local control rate, around 70 to 90% at 2 years, and reduced toxicity, around 5% of grade 3 at 2 years. Four main phase II and III trials are underway in France. Future research concerns the association of stereotactic radiotherapy with immunotherapy or different conventional chemotherapy protocols, the identification of the best clinical presentations, and optimization of fractionation and biological dose for poor prognosis localizations. PMID: 31471251 [PubMed - as supplied by publisher]
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research